Rapid Influenza Diagnostic Testing Market Share Soars Amid Rising Flu Cases 2030
Influenza, a leading cause of mortality, has given rise to approximately 7 million cases in the United States alone in 2019. Seasonal flu remains a serious condition, often necessitating hospitalization for many patients. The urgent need for swift and accurate diagnosis has driven the demand for rapid influenza diagnostic testing (RIDT) in the global market. This demand is particularly critical for high-risk populations, including individuals living with diabetes, cardiovascular conditions, and other chronic ailments. The consistent rise in the use of rapid diagnostic tests as a point-of-care testing method forms a robust foundation for the accelerated adoption of RIDT, primarily driven by its ability to provide rapid and accurate results.
Read More Insights: https://www.fairfieldmarketresearch.com/report/rapid-influenza-diagnostic-testing-ridt-market
Influenza A and B Demand Soars
Influenza A, the more common type, is highly communicable and has been responsible for numerous epidemic outbreaks in the past, resulting in thousands of deaths annually. Such epidemics were popularly referred to as avian flu or bird flu. Influenza A continues to be the top demand generator for rapid influenza diagnostic testing worldwide. Additionally, the prevalence of influenza B is on the rise, as the virus predominantly affects humans. The demand for RIDT for influenza B is also expected to increase in the near future.
The Impact of COVID-19 on RIDT Market Expansion
The availability of improved diagnostic measures has been advantageous for the market. RIDT, a molecular assay, provides rapid results with high accuracy, sensitivity, and specificity. Its ease of use and reliability make RIDT a preferred method for influenza diagnostics, influencing clinical decision-making for diagnosis and treatment. While hospitals are expected to remain the primary consumers, a significant number of diagnostic centers and laboratory testing units are also poised for notable adoption in the near future.
The COVID-19 pandemic has further accelerated the demand for RIDT. With patients often experiencing confusion between flu and COVID-19 due to similar initial symptoms, the rate of flu testing has surged across the United States. However, both viruses differ in terms of serial intervals and associated mortality rates, emphasizing the importance of accurate diagnostic testing for both influenza and COVID-19.
Government and Non-governmental Entities Drive Research
Various research funds have supported market growth through novel influenza research outcomes, aiding in the development of flu diagnostics, vaccines, treatments, and therapeutics. Internationally recognized entities like the National Institute of Allergy and Infectious Disease (NIAID) play a pivotal role in supporting such research studies. Initiatives like the Universal Influenza Vaccine Initiative, backed by government support, are expected to drive the rapid influenza diagnostic testing market. The US Food and Drug Administration (FDA) also enforces stringent regulations for rapid antigen influenza tests, ensuring quality and accuracy.
Pediatrics Segment Emerges as a Lucrative Market
Rapid influenza diagnostic tests are experiencing rapid adoption in the pediatrics segment. The increasing prevalence of influenza among children, necessitating serious measures for severity control, is a significant driver of market growth. High rates of mortality and morbidity among children due to seasonal flu have led to a soaring hospitalization rate, further boosting the market. The prevalence of influenza is also high in adults, especially younger adults, the elderly with comorbidities, and pregnant women, contributing to the growth of the rapid influenza diagnostic testing business.
The US Leads in Technological Advancements
The United States, known for its solid technological advances and research-friendly environment, has been a robust regional ground for the proliferation of the influenza diagnostic testing market. The country’s sophisticated healthcare infrastructure, advancing diagnostics field, skilled professionals, and strong government support elevate the prospects of the US market in the rapid influenza diagnostic testing landscape. In 2017, the FDA reclassified RIDTs as class II devices from class I, mandating specific minimum criteria for sensitivity and specificity.
Canada is also witnessing a rising demand for RIDT, benefiting from exceptional-quality healthcare facilities and a high rate of hospital admissions. Heavy government funding for public education on influenza diagnosis and treatment has further fueled the Canadian market for rapid influenza diagnostic testing.
Promising Opportunities in Asia Pacific
While Asia Pacific remains a key market for RIDT providers due to the expanding flu patient population and the presence of a massive high-risk patient base, the most promising opportunities are anticipated in India and its surrounding regions. The thriving adoption of RIDT kits across India in recent years has contributed to this market’s attractiveness.
Competitive Landscape and Recent Developments
Leading companies in the global rapid influenza diagnostic testing market include Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Hologic, Luminex Corporation, Quidel Corporation, GenMark Diagnostics, Inc., Meridian Bioscience, Inc., Danaher Corporation (Cepheid), Biocartis, bioMérieux Inc, and Endress+Hauser (Analytik Jena AG).
Market leaders are expected to focus on research and innovation as key growth strategies. Acquisitions and collaborations will also be favored by companies seeking a stronger foothold in regional and global markets. In 2020, Sekisui Diagnostics received FDA approval and CLIA Waiver for its OSOM® Ultra Plus Flu A&B Test, aiming to bolster the company’s flu portfolio performance.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 – By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/rapid-influenza-diagnostic-testing-ridt-market
Visit Our Blogs:
https://hackmd.io/@E4v1isUnROG4-prBVaQQGw/H1dK7D6Ch
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
